title: ATXN7 Gene Variants and Expression Predict Post-Operative Clinical Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma.
abstract: OBJECTIVE
  Hepatocellular carcinoma (HCC) is a lethal disease with nearly equal morbidity and mortality. Thus, the discovery and application of more useful predictive biomarkers for improving therapeutic effects and prediction of clinical outcomes is of crucial significance.
  
  
  METHODS
  A total of 475 HBV-related HCC patients were enrolled. Ataxin 7 (ATXN7) single nucleotide polymorphisms (SNPs) were genotyped by Sanger DNA sequencing after PCR amplification. The associations between ATXN7 SNPs and mRNA expression with the prognosis of HBV-related HCC were analyzed.
  
  
  RESULTS
  In all, rs3774729 was significantly associated with overall survival (OS) of HBV-related HCC (P = 0.013, HR = 0.66, 95% CI: 0.48-0.94). And patients with the AA genotype and a high level of serum alpha fetoprotein (AFP) had significantly worse OS when compared to patients with AG/GG genotypes and a low level of AFP (adjusted P = 0.007, adjusted HR = 1.83, 95% CI = 1.18-2.82). Furthermore, low expression of ATXN7 was significantly associated with poor recurrence-free survival (RFS) and OS (P = 0.007, HR = 2.38, 95% CI = 1.27-4.45 and P = 0.025, HR = 1.75, 95% CI = 1.18-2.62).
  
  
  CONCLUSIONS
  ATXN7 may be a potential predictor of post-operative prognosis of HBV-related HCC.
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Chuangye
authors.initials: C
authors.lastname: Han
authors.forename: Long
authors.initials: L
authors.lastname: Yu
authors.forename: Xiaoguang
authors.initials: X
authors.lastname: Liu
authors.forename: Tingdong
authors.initials: T
authors.lastname: Yu
authors.forename: Wei
authors.initials: W
authors.lastname: Qin
authors.forename: Xiwen
authors.initials: X
authors.lastname: Liao
authors.forename: Zhengtao
authors.initials: Z
authors.lastname: Liu
authors.forename: Sicong
authors.initials: S
authors.lastname: Lu
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Chen
authors.forename: Hao
authors.initials: H
authors.lastname: Su
authors.forename: Guangzhi
authors.initials: G
authors.lastname: Zhu
authors.forename: Xue
authors.initials: X
authors.lastname: Qin
authors.forename: Ying
authors.initials: Y
authors.lastname: Gui
authors.forename: Jiaquan
authors.initials: J
authors.lastname: Li
authors.forename: Kaiyin
authors.initials: K
authors.lastname: Xiao
authors.forename: Xigang
authors.initials: X
authors.lastname: Chen
authors.forename: Xinping
authors.initials: X
authors.lastname: Ye
authors.forename: Minhao
authors.initials: M
authors.lastname: Peng
authors.forename: Jiahong
authors.initials: J
authors.lastname: Dong
authors.forename: Tao
authors.initials: T
authors.lastname: Peng
mesh_terms: D000067719:Ataxin-7 / Q000235:genetics* / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000235:genetics* / Q000821:virology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000235:genetics* / Q000821:virology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000067719:Ataxin-7; D012333:RNA, Messenger; D000509:alpha-Fetoproteins